MedTrace Logo

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2018-08-01

No results posted yet for this study

Summary

To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).

Conditions

  • Atopic Disorders
  • Eczema, Atopic

Interventions

DRUG

Dupilumab

Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

DEVICE

Auto-injector Device

Delivery of Dupilumab by auto-injector device

DEVICE

Prefilled syringe

Delivery of Dupilumab by prefilled syringe

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-11-14
Completion
2018-02-12
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03050151 on ClinicalTrials.gov